Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors.

Yang S, Qu S, Perez-Tores M, Sawai A, Rosen N, Solit DB, Arteaga CL
Cancer Res. 2006 66 (14): 6990-7

PMID: 16849543 · DOI:10.1158/0008-5472.CAN-06-1042

Activating mutations in the epidermal growth factor receptor (EGFR), localized in the activation loop within the kinase domain, have been discovered in non-small cell lung cancers (NSCLC). Most of these mutants are exquisitely sensitive to EGFR tyrosine kinase inhibitors, suggesting that they generate receptor dependence in the cancers that express them. 32D cells stably expressing EGFR-L861Q and EGFR-L858R but not wild-type EGFR exhibited ligand-independent receptor phosphorylation and viability. Ligand-induced receptor down-regulation (LIRD) was impaired in mutant-expressing cells. The EGFR mutants were constitutively associated with the E3 ubiquitin ligase Cbl but did not associate with the adaptor protein CIN85 on the addition of ligand. Inhibition of HSP90 activity with geldanamycin restored Cbl function as indicated by receptor ubiquitination and LIRD. These results suggest that EGFR mutants form defective endocytic complexes. In addition, HSP90 plays a role in maintaining the functional conformation of EGFR mutants and protecting activated receptors from LIRD.

MeSH Terms (17)

Animals Cell Survival Down-Regulation ErbB Receptors Female Gene Expression Regulation, Neoplastic HSP90 Heat-Shock Proteins Humans Ligands Lung Neoplasms Mice Mice, Inbred BALB C Mutation Oncogene Protein v-cbl Transfection Transplantation, Heterologous Ubiquitin

Connections (1)

This publication is referenced by other Labnodes entities: